AI assistant
Sending…
Terns Pharmaceuticals, Inc. — Director's Dealing 2025
Nov 6, 2025
32559_dirs_2025-11-05_9e117a96-d5bf-4993-8410-d521456dfc7d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Terns Pharmaceuticals, Inc. (TERN)
CIK: 0001831363
Period of Report: 2025-11-04
Reporting Person: Quigley Jill M. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-11-04 | Common Stock | M | 24520.00 | $9.24 | Acquired | 24520.00 | Direct |
| 2025-11-04 | Common Stock | S | 24520.00 | $18.00 | Disposed | 0.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-11-04 | Stock Option (Right to Buy) | $9.24 | M | 24520.00 | Disposed | 2030-12-29 | Common Stock (24520.00) | Direct |
Footnotes
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2024.
F2: 1/3rd of the shares subject to the option vested on the first anniversary measured from December 29, 2020 (the "Vesting Commencement Date"), and 1/36th of the total number of shares vested monthly thereafter, such that 100% of the shares subject to the option were fully vested and exercisable on the third anniversary of the Vesting Commencement Date.